£495.00

The 2023-2028 Outlook for Testosterone Replacement Therapy for Male Hypogonadism in Japan

Subjects

Price data last checked 16 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 75 days · 75 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 75 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (75 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 75 days

Description

This study covers the latent demand outlook for testosterone replacement therapy for male hypogonadism across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for testosterone replacement therapy for male hypogonadism. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of testosterone replacement therapy for male hypogonadism as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Allergan, AstraZeneca, Bayer, Eli Lilly and Company, Endo International, Ferring International Center, IBSA Institut Biochimique, Laboratoires Genevrier, Merck & Company, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BP9WTJ3P
Category: Books > Subjects
Domain: Amazon UK
Release Date: 28 November 2022
Listed Since: 09 December 2022

The 2023-2028 Outlook for Testosterone Replacement Therapy for Male Hypogonadism in Japan

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Testosterone Replacement Therapy for Male Hypogonadism in China

The 2023-2028 Outlook for Testosterone Replacement Therapy for Male Hypogonadism for US Zip Codes

The 2023-2028 Outlook for Testosterone Replacement Therapy for Male Hypogonadism in India

The 2023-2028 Outlook for Testosterone Replacement Therapy for Male Hypogonadism in the United States

The 2025-2030 World Outlook for Testosterone Replacement Therapy for Male Hypogonadism

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in Japan

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in Europe

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in Asia

The 2025-2030 World Outlook for Testosterone Replacement Therapies

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in The Americas

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in Greater China

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in India

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in Africa

The 2013-2018 World Outlook for Testosterone Replacement Therapy (TRT)

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in Oceana

The 2013-2018 Outlook for Testosterone Replacement Therapy (TRT) in the United States

The 2023-2028 Outlook for Hormone Replacement Therapies in Japan

The 2013-2018 Outlook for Hormone Replacement Therapy (HRT) in Japan

The 2023-2028 Outlook for Hormone Therapy for Prostate Cancer Therapeutics in Japan

Hypogonadism, An Issue of Urologic Clinics of North America (Volume 43-2) (The Clinics: Internal Medicine, Volume 43-2)

The 2013-2018 Outlook for Hormone Replacement Therapy (HRT) in Europe

The 2023-2028 Outlook for Hormone Replacement Therapies in the United States

The 2013-2018 Outlook for Hormone Replacement Therapy (HRT) in India

The 2013-2018 Outlook for Hormone Replacement Therapy (HRT) in Latin America